Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design

Por Cheng, Hengmiao, Li, Chunze, Bailey, Simon, Baxi, Sangita M., Goulet, Lance, Guo, Lisa, Hoffman, Jacqui, Jiang, Ying, Johnson, Theodore Otto, Johnson, Ted W., Knighton, Daniel R., Li, John, Liu, Kevin K.-C., Liu, Zhengyu, Marx, Matthew A., Walls, Marlena, Wells, Peter A., Yin, Min-Jean, Zhu, Jinjiang, Zientek, Michael
Publicado em 2012

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

Por Zou, Helen Y., Li, Qiuhua, Engstrom, Lars D., West, Melissa, Appleman, Vicky, Wong, Katy A., McTigue, Michele, Deng, Ya-Li, Liu, Wei, Brooun, Alexei, Timofeevski, Sergei, McDonnell, Scott R. P., Jiang, Ping, Falk, Matthew D., Lappin, Patrick B., Affolter, Timothy, Nichols, Tim, Hu, Wenyue, Lam, Justine, Johnson, Ted W., Smeal, Tod, Charest, Al, Fantin, Valeria R.
Publicado no Proc Natl Acad Sci U S A (2015)

CNS Anticancer Drug Discovery and Development Conference White Paper

Por Levin, Victor A., Tonge, Peter J., Gallo, James M., Birtwistle, Marc R., Dar, Arvin C., Iavarone, Antonio, Paddison, Patrick J., Heffron, Timothy P., Elmquist, William F., Lachowicz, Jean E., Johnson, Ted W., White, Forest M., Sul, Joohee, Smith, Quentin R., Shen, Wang, Sarkaria, Jann N., Samala, Ramakrishna, Wen, Patrick Y., Berry, Donald A., Petter, Russell C.
Publicado no Neuro Oncol (2015)

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

Por Shaw, Alice T., Friboulet, Luc, Leshchiner, Ignaty, Gainor, Justin F., Bergqvist, Simon, Brooun, Alexei, Burke, Benjamin J., Deng, Ya-Li, Liu, Wei, Dardaei, Leila, Frias, Rosa L., Schultz, Kate R., Logan, Jennifer, James, Leonard P., Smeal, Tod, Timofeevski, Sergei, Katayama, Ryohei, Iafrate, A. John, Le, Long, McTigue, Michele, Getz, Gad, Johnson, Ted W., Engelman, Jeffrey A.
Publicado no N Engl J Med (2015)

PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to 1(st) and 2(nd) generation ALK inhibitors in pre-clinical models

Por Zou, Helen Y., Friboulet, Luc, Kodack, David P., Engstrom, Lars D., Li, Qiuhua, West, Melissa, Tang, Ruth W., Wang, Hui, Tsaparikos, Konstantinos, Wang, Jinwei, Timofeevski, Sergei, Katayama, Ryohei, Dinh, Dac M., Lam, Hieu, Lam, Justine L., Yamazaki, Shinji, Hu, Wenyue, Patel, Bhushankumar, Bezwada, Divya, Frias, Rosa L., Lifshits, Eugene, Mahmood, Sidra, Gainor, Justin F., Affolter, Timothy, Lappin, Patrick B., Gukasyan, Hovhannes, Lee, Nathan, Deng, Shibing, Jain, Rakesh K, Johnson, Ted W., Shaw, Alice T., Fantin, Valeria R., Smeal, Tod
Publicado no Cancer Cell (2015)